Log in to save to my catalogue

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprote...

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprote...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1080620526

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

About this item

Full title

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

Publisher

London: Elsevier Ltd

Journal title

The Lancet infectious diseases, 2012-08, Vol.12 (8), p.597-607

Language

English

Formats

Publication information

Publisher

London: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently licensed. A bivalent recombinant factor H-binding protein vaccine (recombinant lipoprotein 2086) has been developed to provide broad coverage against diverse invasive meningococcus serogroup B s...

Alternative Titles

Full title

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1080620526

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1080620526

Other Identifiers

ISSN

1473-3099

E-ISSN

1474-4457

DOI

10.1016/S1473-3099(12)70087-7

How to access this item